Related Experiment Videos
Cerebrospinal fluid (CSF) and serum S100B: release and wash-out pattern
1Department of Neuroimmunology of the Institute of Neurology, Queen Square, WC1N 3BG London, UK.
Brain Research Bulletin
|August 12, 2003
Summary
This study measured S100B protein in cerebrospinal fluid and serum to monitor brain injury. S100B levels correlate with injury severity, pathology, and time, offering a valuable biomarker for traumatic brain injury and hemorrhage.
Area of Science:
- Neuroscience
- Biochemistry
- Clinical Diagnostics
Background:
- S100B is a key brain-specific protein.
- It indicates astrocyte damage and activation.
- Monitoring S100B aids in assessing neurological conditions.
Purpose of the Study:
- To measure S100B levels in cerebrospinal fluid (CSF) and serum.
- To evaluate S100B as a biomarker in patients with traumatic brain injury (TBI), subarachnoid hemorrhage (SAH), and intracranial hemorrhage (ICH).
- To analyze the release and washout patterns of S100B in relation to injury characteristics.
Main Methods:
- Development of a straightforward, in-house ELISA technique.
- Measurement of S100B in CSF and serum samples.
- Inclusion of patients with TBI, SAH, ICH, and normal controls (NC).
Main Results:
- S100B levels were quantified in CSF and serum across different patient groups.
- Observed release and washout patterns provide insights into S100B dynamics.
- Findings relate S100B levels to mass effect, pathology, and time.
Conclusions:
- S100B is a reliable biomarker for monitoring brain injury.
- The study highlights the utility of S100B in diagnosing and managing TBI, SAH, and ICH.
- CSF and serum S100B measurements offer valuable diagnostic information.